4D MOLECULAR THERAPEUTICS, INC. Funds and ETFs 4D Molecular Therapeutics, Inc.
Equities
FDMT
US35104E1001
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.7 USD | +0.23% |
|
-2.58% | +26.85% |
ETFs positioned on 4D Molecular Therapeutics, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.74% | 0 M€ | -4.02% | ||
| 0.06% | 0 M€ | 0.00% | - | |
| 0.05% | 2 M€ | -.--% | ||
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | +9.18% | - | |
| 0.00% | 0 M€ | +4.20% | - | |
| 0.00% | 0 M€ | +3.63% | - |
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
25.7
USD
Average target price
52.3
USD
Spread / Average Target
+103.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.85% | 1.33B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- FDMT Stock
- Funds and ETFs 4D Molecular Therapeutics, Inc.